Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of IDEAYA Biosciences in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs ...
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
CVS Health investors will closely examine this week turnaround initiatives spearheaded by new CEO David Joyner and their ...
Fintel reports that on February 7, 2025, Leerink Partners upgraded their outlook for Doximity (NYSE:DOCS) from Market Perform ...
After a rough 2024, Teladoc Health (TDOC) has seen its shares surge up roughly 45% year-to-date, catalyzed by a recent ...
Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
Leerink downgraded Hologic (HOLX) to Market Perform from Outperform with a price target of $75, down from $80, following the fiscal Q1 report.
An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...